

likely acquired when animals were housed in enclosures previously occupied by infected raccoons or when bedding or food became contaminated with *B. procyonis*-infected raccoon feces. In *B. procyonis*-endemic areas, cages used to house raccoons should be thoroughly decontaminated by flaming, or cages should be dedicated for use by raccoons. Because *B. procyonis* roundworms can spread to other animals, persons in contact with raccoons should be alert to potential transmission routes and apply appropriate biosecurity procedures.

This work was supported by a grant from the Southeast Center for Emerging Biologic Threats and the Centers for Disease Control and Prevention.

**Emily L. Blizzard,
Michael J. Yabsley,
Margaret F. Beck,
and Stefan Harsch**

Author affiliations: University of Georgia, Athens, Georgia, USA (E.L. Blizzard, M.J. Yabsley); Goose Creek Wildlife Sanctuary, Tallahassee, Florida, USA (M.F. Beck); and SPCA Wildlife Care Center, Ft. Lauderdale, Florida, USA (S. Harsch)

DOI: 10.3201/eid1611.100549

References

1. Kazacos KR. *Baylisascaris procyonis* and related species. In Samuel WM, Pybus MJ, Kocan AA, editors. Parasitic diseases of wild mammals. 2nd ed. Ames (IA): Iowa State University Press; 2001. p. 301–41.
2. Owen SF, Edwards JW, Ford WM, Crum JM, Wood DB. Raccoon roundworm in raccoons in central West Virginia. *Northeastern Naturalist*. 2004;11:137–42. DOI: 10.1656/1092-6194(2004)011[0137:RRIRIC]2.0.CO;2
3. McCleery RA, Foster GW, Lopez RR, Peterson MJ, Forrester DJ, Silvy NJ. Survey of raccoons on Key Largo, Florida, USA, for *Baylisascaris procyonis*. *J Wildl Dis*. 2005;41:250–2.
4. Souza MJ, Ramsay EC, Patton S, New JC. *Baylisascaris procyonis* in raccoons (*Procyon lotor*) in eastern Tennessee. *J Wildl Dis*. 2009;45:1231–4.
5. Eberhard ML, Nace EK, Won KY, Punkosdy GA, Bishop HS, Johnston SP. *Baylisascaris procyonis* in the metropolitan Atlanta area. *Emerg Infect Dis*. 2003;9:1636–7.
6. Blizzard EL, Davis CL, Henke S, Long DB, Hall CA, Yabsley MJ. Distribution, prevalence, and genetic characterization of *Baylisascaris procyonis* in selected areas of Georgia. *J Parasitol*. In press 2010.
7. Zhu X, Gasser RB, Chilton NB. Differences in the 5.8S rDNA sequences among ascarid nematodes. *Int J Parasitol*. 1998;28:617–22. DOI: 10.1016/S0020-7519(97)00214-2
8. Zhu XQ, Podolska M, Liu JS, Yu HQ, Chen HH, Lin ZX, et al. Identification of anisakid nematodes with zoonotic potential from Europe and China by single-strand conformation polymorphism analysis of nuclear ribosomal DNA. *Parasitol Res*. 2007;101:1703–7. DOI: 10.1007/s00436-007-0699-0
9. Forrester DJ. Raccoons. In Forrester DJ. Parasites and diseases of wild mammals in Florida, 1st ed. Gainesville (FL): University of Florida Press; 1992. p. 123–50.

Address for correspondence: Michael J. Yabsley, Southeastern Cooperative Wildlife Disease Study—College of Veterinary Medicine, University of Georgia, Wildlife Disease Bldg, Athens, GA 30605, USA; email: myabsley@uga.edu

Vibrio cholerae O1 Variant with Reduced Susceptibility to Ciprofloxacin, Western Africa

To the Editor: Many variants of cholerae vibrios have emerged since the beginning of the seventh pandemic, indicating continuous evolution of this pathogenic agent. Variations occur mainly in genetic determinants of virulence and antimicrobial drug susceptibility. In September–October 2009, concurrent outbreaks of acute watery diarrhea in northeastern

Nigeria (4,559 cases) and northern Cameroon (696 cases) were investigated by state ministries of health. We report reduced sensitivity to ciprofloxacin in *Vibrio cholerae* O1 strains and the atypical cholera toxin B (*ctxB*) genotype of these strains.

In September–October 2009, stool specimens from patients in Nigeria were collected on filter paper, moistened with sterile physiologic saline, and sent at room temperature to the National Reference Center for Vibrios and Cholera at the Institut Pasteur (Paris, France). Ten *V. cholerae* O1 biotype El Tor serotype Ogawa strains were isolated and identified by using standard procedures. Concurrently in Cameroon, 9 *V. cholerae* O1 Ogawa strains isolated from patient stool samples by the bacteriology laboratory of the Pasteur Center (Garoua, Cameroon) were sent to the National Reference Center for Vibrios and Cholera.

All strains were tested for antimicrobial susceptibility by MIC determination to tetracycline, trimethoprim/sulfamethoxazole, sulfonamides, ampicillin, chloramphenicol, nalidixic acid, and ciprofloxacin by using Etest (AB bioMérieux, Solna, Sweden) according to Clinical and Laboratory Standards Institute procedures and interpretative standards for *V. cholerae* (1). PCR amplification of the genes encoding DNA gyrase (*gyrA* and *gyrB*) and topoisomerase IV (*parC* and *parE*) and subsequent sequencing of PCR products were performed (2).

PCR was used to test for the presence of *ctxA* and *ctxB* genes, which encode the cholera toxin (CT), and the *tcpA* gene, which encodes the toxin-coregulated pilus. Genotyping of *ctxB* was performed by sequencing PCR products.

All isolates showed susceptibility to tetracycline (MIC 1.5 mg/L), intermediate susceptibility to ampicillin (MICs 12–16 mg/L) and chloramphenicol (MICs 8–12 mg/L), and resistance to trimethoprim/sulfamethoxazole

(MIC >32 mg/L), sulfonamides (MIC >1,024 mg/L), and nalidixic acid (MIC >256 mg/L). MICs of ciprofloxacin ranged from 0.25 to 0.5 mg/L.

Sequencing of *gyrA*, *gyrB*, *parC*, and *parE* genes among all strains detected 1 mutation in *gyrA* (substitution of serine by isoleucine at position 83) and 1 mutation in *parC* (substitution of serine by leucine at position 85). Both point mutations have been associated with quinolone resistance in clinical isolates of *V. cholerae* (2). None of the strains had any mutations in *gyrB* or *parE*.

The presence of *ctxA* and *ctxB* genes confirmed the toxigenicity of all isolates, and *tcpA* PCR product size and sequence identified El Tor biotype strains. The DNA sequence of *ctxB* was similar to that of the recently reported Orissa variant identified in India in 2007 (3). This sequence had 2 mutations resulting in histidine at position 39 and threonine at position 68 (this amino acid sequence is similar to the CT-B subunit of the reference classical strain) and a third mutation resulting in substitution of histidine by asparagine at position 20.

We report atypical El Tor strains of *V. cholerae* O1 and their reduced susceptibility to ciprofloxacin in Nigeria and Cameroon. Since the 1990s, atypical El Tor strains that produce classical CT have been increasingly reported from countries in Asia, where they have gradually replaced the prototype El Tor strains, but they have only been reported in 2 countries in Africa (Mozambique and Zambia) (4,5). On the basis of the CT-B subunit sequence, these variants differ from variants isolated in southern Africa and from most variants isolated in Asia by having the same modified classical CT as a strain recently isolated in Orissa in eastern India (3), which has not been reported elsewhere. These findings indicate evolution of *V. cholerae* O1 El Tor hybrid strains. Their presence may indicate spread of strains from eastern India to Africa (6).

The presence of CT-B variants in central or western Africa is of great concern because these strains may be more toxigenic (3). There is also concern for the strains isolated in this study because of their reduced susceptibility to ciprofloxacin. Although reduced susceptibility to fluoroquinolone is common in southern Asia (7,8), it was reported in Africa (Zimbabwe) only recently (9). Our findings, in addition to the report of Islam et al. (9), indicate that *V. cholerae* with reduced sensitivity to a fluoroquinolone is present in southern and western Africa. These results highlight the need for continued monitoring of antimicrobial drug susceptibility and strain tracking to maintain an efficient cholera surveillance system.

This study was partially supported by a grant from the French Institute for Public Health Surveillance and by the Institut Pasteur.

**Marie-Laure Quilici,
Denis Massenet, Bouba Gake,
Barem Bwaki,
and David M. Olson**

Author affiliations: Institut Pasteur, Paris, France (M.-L. Quilici); Centre Pasteur Cameroun, Garoua, Cameroon (D. Massenet, B. Gake); State Epidemiologic Unit, Yola, Adamawa State, Nigeria (B. Bwaki); and Doctors Without Borders/Médecins Sans Frontières, New York, New York, USA (D. M. Olson)

DOI: 10.3201/eid1611.100568

References

1. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing; 18th informational supplement. CLSI document M100–S18. Wayne (PA): The Institute; 2008.
2. Baranwal S, Dey K, Ramamurthy T, Nair GB, Kundu M. Role of active efflux in association with target gene mutations in fluoroquinolone resistance in clinical isolates of *Vibrio cholerae*. *Antimicrob Agents Chemother*. 2002;46:2676–8. DOI: 10.1128/AAC.46.8.2676-2678.2002
3. Goel AK, Jiang SC. Genetic determinants of virulence, antibiogram and altered biotype among the *Vibrio cholerae* O1 isolates from different cholera outbreaks in India. *Infect Genet Evol*. 2010;10:815–9.
4. Ansaruzzaman M, Bhuiyan NA, Nair GB, Sack DA, Lucas M, Deen JL, et al. Cholera in Mozambique, variant of *Vibrio cholerae*. *Emerg Infect Dis*. 2004;10:2057–9.
5. Safa A, Sultana J, Cam PD, Mwansa JC, Kong RY. *Vibrio cholerae* O1 hybrid El Tor strains, Asia and Africa. *Emerg Infect Dis*. 2008;14:987–8. DOI: 10.3201/eid1406.080129
6. Safa A, Nair GB, Kong RY. Evolution of new variants of *Vibrio cholerae* O1. *Trends Microbiol*. 2010;18:46–54. DOI: 10.1016/j.tim.2009.10.003
7. Garg P, Chakraborty S, Basu I, Datta S, Rajendran K, Bhattacharya T, et al. Expanding multiple antibiotic resistance among clinical strains of *Vibrio cholerae* isolated from 1992–7 in Calcutta, India. *Epidemiol Infect*. 2000;124:393–9. DOI: 10.1017/S0950268899003957
8. Krishna BV, Patil AB, Chandrasekhar MR. Fluoroquinolone-resistant *Vibrio cholerae* isolated during a cholera outbreak in India. *Trans R Soc Trop Med Hyg*. 2006;100:224–6. DOI: 10.1016/j.trstmh.2005.07.007
9. Islam MS, Midzi SM, Charimari L, Cravito A, Endtz HP. Susceptibility to fluoroquinolones of *Vibrio cholerae* O1 isolated from diarrheal patients in Zimbabwe. *JAMA*. 2009;302:2321–2. DOI: 10.1001/jama.2009.1750

Address for correspondence: David M. Olson, Doctors Without Borders/Médecins Sans Frontières, 333 Seventh Ave, 2nd Floor, New York, NY 10001, USA; email: david.olson@newyork.msf.org

Search
past issues

EID
online
www.cdc.gov/eid